Methods for diagnosing urinary tract and prostatic disorders
First Claim
Patent Images
1. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 3, 6, 8-11, and 18.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are methods of detecting urinary tract and prostatic disorders using reference profiles. Also disclosed are methods of identifying agents for treating urinary tract and prostatic disorders.
-
Citations
24 Claims
- 1. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 3, 6, 8-11, and 18.
-
3. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 6 and 24-55.
-
4. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 3, 8-11, 18, 56-95.
- 5. A method of metabolomically predicting whether a subject is predisposed to developing a urinary tract disorder, comprising obtaining a urinary tract disorder reference profile from said subject and comparing the urinary tract disorder reference profile from said subject with a control urinary tract disorder reference profile, thereby predicting whether the subject is predisposed to having a urinary tract disorder.
- 7. A method for identifying markers indicative of a urinary tract disorder in a subject comprising determining the levels of one or more analytes or metabolites thereof in a subject sample, wherein said analytes or metabolites are selected from the group consisting of UTD 3, 6, 8-11, and 18 and determining those analytes or metabolites that are present in a different concentration in the subject sample compared to a control sample, wherein the presence of said analytes or metabolite at a different concentration is indicative of a urinary tract disorder in said subject.
- 11. A method of diagnosing a urinary tract disorder (UTD) or a predisposition to developing a urinary tract disorder in a subject, comprising determining a level of a UTD-associated analyte in a subject derived sample, wherein an increase or decrease of said level compared to a normal control level indicates that said subject suffers from or is at risk of developing a urinary tract disorder.
- 16. A method of assessing the efficacy of a treatment of a urinary tract disorder in a subject, comprising determining a level of a UTD-associated analyte in a subject sample derived after treatment and comparing said level to a normal control level, thereby monitoring the treatment of the urinary tract disorder in said subject.
-
18. A method of determining the risk of developing a urinary tract disorder in a subject, comprising detecting an elevated concentration of an analyte or metabolite thereof selected from the group consisting of UTD 6 and 24-55 compared to the concentration of said analyte or metabolite in a control sample, wherein an elevated concentration of said analyte or metabolite indicates said subject is at risk of developing a urinary tract disorder.
-
19. A method of determining the risk of developing a urinary tract disorder in a subject, comprising detecting a decreased concentration of an analyte or metabolite thereof selected from the group consisting of UTD 3, 8-11, 18 and 56-95 compared to the concentration of said analyte or metabolite in a control sample, wherein a decreased concentration of said analyte or metabolite indicates said subject is at risk of developing a urinary tract disorder.
-
20. A method of identifying an agent that modulates the onset or progression of a urinary tract disorder in a subject, comprising:
-
i) contacting said subject with a candidate agent;
ii) determining a test level of an analyte in a sample derived from said subject following said contacting;
iii) comparing said test level with a reference level of said analyte, wherein an increase or decrease of said test level relative to said reference level indicates that said test agent modulates the onset or progression of a urinary tract disorder. - View Dependent Claims (21, 22, 23)
-
-
24. A kit comprising a detection reagent that identifies one or more analytes selected from the group consisting of UTD 3, 6, 8-11, 18, and 24-95.
Specification